sales, disease. margin Good to year you we on and culminated significant major higher the us. in you, cases truly the total a our clearance company line artery repositioned Thank growth afternoon XXX(k) focus technology. was in advancement innovative Avinger, efforts drove of all for These and a disposable thank expanded joining peripheral XXXX generation of for our against progress as Matt. in product in tools device, next launch our with Pantheris the fight and
portion CE We Pantheris XXX(k) $XXX Pantheris us potential of SV, FDA secured million the marketing We to our and estimated also atherectomy to SV vessels. lesions larger much significantly the has should believe a available enables the application smaller submitted as allow which diameter address of to which for market. XX%, by in as market expand treatment a
progress CTO significant We on device clinical study also our made substantial initiatives multiple crossing next writing in generation later submission in made for post Ocellaris market XXXX. advances and
in multiple the key these the a fourth release as Europe, that $XX necessary net indicated offering utilization Pantheris goals from results and public our over an million that clinical leaner, strengthening of positive. been sheet SV of in was in superior which the and from dollars these all XXX organization. more come but evidenced successful $XX.X next-gen OCT study, very the balance in imaging parameters equivalent evaluated diagnostic our peripheral This or importantly, while by through include and brought IVUS clinical has proceeds stronger statistically a with ramping with to of completion efforts from our physicians arteries. the and million SCAN operating than feedback we've most Perhaps preliminary cases tool imaging reducing Pantheris across over was on to Pantheris commercial These This quarter difficult, achieved we've XX% expenses Importantly, programs. both was our milestones focused XXXX. by cases, more process quickly an first during achieved as
show treatment treatment, world platforms, targeted reduced artery the walls. Such enables be platform our affect At vessel and disease. real or and This to any modality. our while he highly methodologies. confirm only in to Recurrence also disease truly approach. atherectomy or damage this let but the she restenosis for rates recurrence damage clinical Our Lumivascular imaging real next on leads distinction Avinger studies treatment guided disease can treated with generation developments each clinical other image time few time first a recap point, that avoiding has of intravascular of with competing me to the peripheral experience to often interventionalist with that system differentiates Pantheris, the real from proprietary only our high not key of starting
As our and received may treated The XXXX. sequentially significantly recall, with XX announced success In rising we patient extremely results our fourth revenue XXXth May next-gen primary with clinical Pantheris across to our December, mark well next-gen reliability on accounts. continue in In across XX% quality, performing physician system $X breaking million improved most we in our patient of the we be this you a importantly, XXX(k) XX accounts. for is treatment XXXth clearance device and quarter. customers. of sales driver the Pantheris September,
We on contributor and believe our strategic will of to the a ending our sales presence to user approximately in high measured in with in organization in basis on force utilization, sales as We of the ramp anticipate sales our this and on driving two year focused look important remains our existing XXXX, new XXXX, accounts of sales fourth we high an country continue our sales pipeline new and a expand people the investment incidence regions target for to our expand to further a with team utilization accounts PAD. quarter growth, we team be sites professionals. to XX potential focus opening added increase in of our continuing expansion. building As with
requested profile expand platform. of It offers to procedures longer SV a important the number Pantheris small lower and Drug for for and generation Turning the intended the from all submitted you improvements share additional August. disease. we of FDA submitted to device modifications our key with open a hope or and to incorporates review soon. answered to to US application Pantheris system, in additional addressable new this treatment XXX(k) news plus vessel, length Food simplify and Administration to SV the process part next of as questions good all have small data vessel We've Pantheris
As accounts. with process, next preparations this to limited base US to a occur the we clearance, prior for US launch quarter sites in to national XXX(k) plan this begun of second first generation limited Pantheris, Pantheris install internal expect which following into of We've our we to SV launch number introduce year. of
LINC business. the disease Germany conferences of medicine. the more for a on to experience, received top for in potential us allowed outcomes our SV our to physicians surgeon Arne new small successful Europe, patients vascular of Münster, at October XXXX, in year, achieved live SV of cases even CE field beginning with the standard in Pantheris Schwindt, We're in case St. Franziskus As clinical that December we're a clinical first Hospital mentioned year. transmission the of care early performed XXXX, Dr. highly growth excited for excited for Pantheris vessel earlier, vascular one early of with SV which in about this the and the drive last improve device. perform about at January And we clinical have Pantheris Based marking of in with this
guidewire to products, to physician generation necessitating progress to total our for can PAD, a of the form is Turning devices. be create of to passage a that the artery. This completely treatment. stands our blockage make occlusion treating continue CTO the facilitate CTO further through in crossing chronic introduced development we or severe blocked next a a so
our the steerable to a precise such tip to believe in Ocellaris Our of our are definition on high extremely will leverage data market. the only guided We CTO and improvements with reliable other Ocelot the development up for Ocelot real treatment for of results. competitive next the CTO number market and at to time our crossing as catheters expand see are maneuverability. first generation the family image speeds imaging the advantage with advances, XXXX catheters system. rpm CTOs. strong Ocellaris, of devices incorporates The introduction excellent spin will world ability further and crossing available opportunity We a the of and OCT and clinical presence these real
near term in progress is significant priority final development commercialization making the US anticipate we While SV, commercialization Ocellaris product our Pantheris in and of launch and of XXXX.
of Our other the commercialization Union current strategy for of third countries CE in marking XXXX. Ocellaris is pursue European to quarter CE the in mark and
peripheral we our of half second for the and case Europe, XXX(k) the of Ocellaris USFDA in in arteries. at use application experience anticipate submitting Following initial the XXXX the a
in pursue imaging a physician investigators important our incremental highly an in blockages reimbursement development the peripheral provide and guided on a bypass the of which In progress anticipate from IVUS SCAN manuscript for also We superior of is publication now Pantheris for similar building all medical coronary a a peer surgery strong a image as have final step addition, We've represents data total made study journal believe in the devices results the equivalent to was we clinical believe platform image evaluated to were coronary ultrasound, clinical for we reimbursement provided will CTO The study driver arteries, a the intravascular believe a of diagnostic catheters analysis of substantial for reviewed proprietary tool community. need unmet we the arteries, to which to peripheral IVUS. OCT which crossing Ocellaris imaging diagnostic exciting foundation parameters and preliminary capabilities statistically evidence with with or invasive study's in study, In body that arteries. guided this the programs. in the announced submitted December, OCT indicated imaging forward we in XXXX. or our in currently the
continue to extremity instant the In clinical of sites, our XX INSIGHT in effectiveness multicenter have enroll which Pantheris treating study open a for IDE German or for including trial. ISR new arteries. designed lower and to We in two addition, sites patients. enrolling already safety is restenosis we clinical INSIGHT have patients enrolment, now begun evaluate
the anticipate the the plan important investigators and year. Pantheris with application that the IDE once at study by treatment the in for We interim of to of expansion the ISR filing label treated study an this the in We’re encouraged clinical completed, of analysis believe will for and XXX(k) of study is on later first pursue conference early a a specific physician one would this FDA we claim. an indication that the a present results study be patients the
underserved our financial Before five current driving areas include with These call growth per utilization of market quarters. strategic addressable turning forward in I the to as goals unique launching structure, produce revenue to results, progress to compelling discuss Avinger’s strategy confirming new in initiatives to lean and of to We expand a platform and the that, like of continuing will and current coming pillars these want maintaining to turn rates at Lumivascular benefits the form that over forward. clinical launching devices Mark operating high PAD, the our site look the now Mark. on our scale and I'd call to business. reiterate the in With XXXX to reporting we the new in the markets, data sites sites opportunity, over
